Abstract
Background Longer-term consequences after SARS-CoV-2 infection are becoming an important burden to societies and healthcare systems. Data on post-COVID-19 syndrome in the general population are required for the timely planning of healthcare services and resources. The objective of this study was to assess the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterize their healthcare utilization.
Methods This population-based prospective cohort study (Zurich SARS-CoV-2 Cohort) enrolled 431 adults from the general population with polymerase chain reaction-confirmed SARS-CoV-2 infection reported to health authorities between 27 February 2020 and 05 August 2020 in the Canton of Zurich, Switzerland. We evaluated the proportion of individuals reporting not to have fully recovered since SARS-CoV-2 infection, and the proportion reporting fatigue (Fatigue Assessment Scale), dyspnea (mMRC dyspnea scale) or depression (DASS-21) at six to eight months after diagnosis. Furthermore, the proportion of individuals with at least one healthcare contact after their acute illness was evaluated. Multivariable logistic regression models were used to assess factors associated with these main outcomes.
Results Symptoms were present in 385 (89%) participants at diagnosis and 81 (19%) were initially hospitalized. At six to eight months, 111 (26%) reported not having fully recovered. 233 (55%) participants reported symptoms of fatigue, 96 (25%) had at least grade 1 dyspnea, and 111 (26%) had DASS-21 scores indicating symptoms of depression. 170 (40%) participants reported at least one general practitioner visit related to COVID-19 after acute illness, and 10% (8/81) of initially hospitalized individuals were rehospitalized. Individuals that have not fully recovered or suffer from fatigue, dyspnea or depression were more likely to have further healthcare contacts. However, a third of individuals (37/111) that have not fully recovered did not seek further care.
Conclusions In this population-based study, a relevant proportion of participants suffered from longer-term consequences after SARS-CoV-2 infection. With millions infected across the world, our findings emphasize the need for the timely planning of resources and patient-centered services for post-COVID-19 care.
Registration ISRCTN14990068
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN14990068
Funding Statement
The Zurich SARS-CoV-2 Cohort study is part of the Corona Immunitas research program, coordinated by the Swiss School of Public Health (SSPH+) and funded through SSPH+ fundraising, including funding by the Swiss Federal Office of Public Health, the Cantons of Switzerland (Basel, Vaud and Zurich), private funders (ethical guidelines for funding stated by SSPH+ were respected) and institutional funds of the participating universities. Additional funding specific to this study was provided by the Cantonal Health Directorate Zurich and the University of Zurich Foundation. Study funders had no role in the study design, data collection, analysis, interpretation, or writing of this report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the responsible ethics committee of the Canton of Zurich, Switzerland (Kantonale Ethik-Kommission Zürich; BASEC-Nr. 2020-01739).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Title updated; Author affiliations updated; Abstract revised and shortened; Main text revised for more concise wording (shortened, no previously included information omitted); Original Figure 2 moved to Supplementary Material; New Figure 2 and Figure 3 on associations added; Supplementary Material updated (Figure S1 added, Tables S1-S8 reordered).
Data Availability
We are open to sharing de-identified individual participant data that underlie the results reported in this article. Requests can be made to the corresponding author. Data requestors will need to sign a data access agreement.
List of abbreviations
- AIC
- Akaike Information Criterion
- CI
- Confidence Interval
- COVID-19
- Coronavirus disease 2019
- DASS-21
- 21-item Depression, Anxiety and Stress Scale
- EQ-5D-5L
- EuroQol 5-dimension 5-level
- EQ VAS
- EuroQol Visual Analogue Scale
- FAS
- Fatigue Assessment Scale
- IQR
- Interquartile range
- mMRC
- Modified Medical Research Council
- OR
- Odds Ratio
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
